Global Companion Diagnostic Technologies Market Size
Estimates for the companion diagnostic technologies market place it at a valuation of US$ 7.9 billion in 2024 and a compound annual growth rate (CAGR) of 11.60% to reach US$ 21.4 billion by 2034.
The goal of the companion diagnostics technologies market is to supply a range of molecular tests that offer crucial data for the secure and efficient administration of medications. These examinations assist medical practitioners in determining if a given therapy or course of treatment is best for the patient and will ultimately result in the disease's cure. In the customized medicine approach, companion diagnostics are essential because they let medical professionals treat patients with greater knowledge.
The primary cause driving the target market's expansion is the rising incidence of infectious diseases such as cancer. An increasing number of cases of cancer are recorded each year, making it one of the top causes of mortality worldwide. Furthermore, infectious diseases still provide significant health risks, particularly in light of the advent of the development of novel strains and the reappearance of diseases under control, which ultimately fuels the market for companion diagnostic technologies.
As per The International Agency for Research on Cancer (IARC), the number of newly diagnosed cases of cancer worldwide in 2012 was approximated to be 14.1 million. Lung cancer accounted for 13 percent of these, with breast cancer coming in at 11.9 percent and colorectal cancer at 11.9%. Furthermore, the Hindu reports from 2023 indicate that the possibility of climate change is about to result in an increase in the burden associated with the development of diseases like dengue, malaria, and chikungunya.